歌礼制药在港交所公告小分子口服GLP-1R激动剂ASC30美国13周IIa期研究完成首批肥胖或超重受试者给药。在美国Ib期研究中ASC30每日一次口服片显示经4周治疗后安慰剂校准后的相对基线的平均体重下降高达6.5%。预计2025年第四季度获得ASC30口服13周IIa期研究的顶线数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.